Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021058038 - USE OF CD200 PROTEIN AND CD200 FUSION PROTEIN IN PREPARING A DRUG FOR TREATING PSORIASIS

Publication Number WO/2021/058038
Publication Date 01.04.2021
International Application No. PCT/CN2020/123629
International Filing Date 26.10.2020
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 47/68 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 17/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
CPC
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61P 17/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
Applicants
  • 中国药科大学 CHINA PHARMACEUTICAL UNIVERSITY [CN]/[CN]
Inventors
  • 徐寒梅 XU, Hanmei
  • 李东平 LI, Dongping
  • 金欣荣 JIN, Xinrong
Agents
  • 江苏瑞途律师事务所 RAYTO PARTNERS, P.C.
Priority Data
201910898038.823.09.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF CD200 PROTEIN AND CD200 FUSION PROTEIN IN PREPARING A DRUG FOR TREATING PSORIASIS
(FR) UTILISATION D'UNE PROTÉINE CD200 ET D'UNE PROTÉINE DE FUSION CD200 DANS LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ AU TRAITEMENT DU PSORIASIS
(ZH) CD200蛋白和CD200融合蛋白在制备治疗银屑病药物中的应用
Abstract
(EN)
A use of a CD200 extracellular domain protein or a fusion protein formed from a CD200 extracellular domain protein and an Fc fragment in preparing a drug for treating psoriasis.
(FR)
La présente invention concerne une utilisation d'une protéine de domaine extracellulaire CD200 ou d'une protéine de fusion formée à partir d'une protéine de domaine extracellulaire CD200 et d'un fragment Fc dans la préparation d'un médicament destiné au traitement du psoriasis.
(ZH)
本发明提供CD200胞外区蛋白或CD200胞外区蛋白与Fc片段形成的融合蛋白在制备治疗银屑病药物中的应用。
Also published as
Latest bibliographic data on file with the International Bureau